-
1.发明申请HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS 审中-公开作为CANNABINOID CB1受体拮抗剂的异氟醚咪唑衍生物公开(公告)号：US20080207704A1
公开(公告)日：2008-08-28
申请号：US11679742
申请日：2007-02-27
申请人： Jinhwa Lee , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn
发明人： Jinhwa Lee , Jeongmin Kim , Jong Yup Kim , Hee Jeong Seo , Myung Eun Jung , Sung-Han Lee , Kwangwoo Ahn
IPC分类号： A61K31/41 , A61K31/422 , A61K31/4245 , A61K31/427 , C07D413/04 , C07D417/04
CPC分类号： C07D417/04 , C07D413/04
摘要： A heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing a heteroaryl-imidazole compound of formula (I), a pharmaceutical composition containing a heteroaryl-imidazole compound of formula (I), and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的杂芳基 - 咪唑化合物或其药学上可接受的盐作为大麻素CB 1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和与肥胖相关的代谢紊乱 。 本发明还提供了制备式（I）的杂芳基 - 咪唑化合物的方法，含有式（I）的杂芳基 - 咪唑化合物的药物组合物，以及预防或治疗肥胖症和与肥胖有关的代谢紊乱的方法。
-
2.发明申请NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 有权新颖的含有阿维菌素的咪唑烷四羧酰胺衍生物和包含其的药物组合物公开(公告)号：US20120115881A1
公开(公告)日：2012-05-10
申请号：US13383143
申请日：2010-07-09
申请人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
发明人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
IPC分类号： A61K31/497 , A61P25/24 , C07D403/12
CPC分类号： C07D417/14 , A61K31/496 , C07D233/88 , C07D401/12 , C07D403/06 , C07D405/04
摘要： A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
摘要翻译： 提供了一种新的含有芳基哌嗪的咪唑-4-甲酰胺衍生物或其药学上可接受的盐，以及包含其作为预防或治疗抑郁障碍的活性成分的药物组合物。
-
3.发明授权Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same 有权含有芳基哌嗪的咪唑4-甲酰胺衍生物和包含其的药物组合物公开(公告)号：US08835436B2
公开(公告)日：2014-09-16
申请号：US13383143
申请日：2010-07-09
申请人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong Yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho Kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
发明人： Jinhwa Lee , Hee Jeong Seo , Suk Youn Kang , Eun-Jung Park , Min Ju Kim , Suk Ho Lee , Jong Yup Kim , Jeongmin Kim , Myung Eun Jung , Hyun Jung Kim , Mi-soon Kim , Ho Kyun Han , Kwang Woo Ahn , Min Woo Lee , Ki-Nam Lee , Ae Nim Pae , Woo-Kyu Park
IPC分类号： A61K31/496 , C07D233/88 , C07D401/12 , C07D403/06 , C07D405/04 , C07D417/14
CPC分类号： C07D417/14 , A61K31/496 , C07D233/88 , C07D401/12 , C07D403/06 , C07D405/04
摘要： A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.
摘要翻译： 提供了一种新的含有芳基哌嗪的咪唑-4-甲酰胺衍生物或其药学上可接受的盐，以及包含其作为预防或治疗抑郁障碍的活性成分的药物组合物。
-
4.发明授权公开(公告)号：US07875647B2
公开(公告)日：2011-01-25
申请号：US11863501
申请日：2007-09-28
申请人： Jinhwa Lee , Jeong Min Kim , Chong-Hwan Jonathan Chang , Suk Ho Lee , Hee Jeong Seo , Suk Youn Kang , Kwang-Seop Song , Jong Yup Kim , Min-ah Kim , Sung-han Lee , Kwang-Woo Ahn , Myung Eun Jung , Ji-Hyun Park
发明人： Jinhwa Lee , Jeong Min Kim , Chong-Hwan Jonathan Chang , Suk Ho Lee , Hee Jeong Seo , Suk Youn Kang , Kwang-Seop Song , Jong Yup Kim , Min-ah Kim , Sung-han Lee , Kwang-Woo Ahn , Myung Eun Jung , Ji-Hyun Park
IPC分类号： A61K31/415 , A61K31/4196 , C07D231/10 , C07D285/12 , C07D417/14
CPC分类号： C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的杂芳基 - 吡唑化合物或其药学上可接受的盐作为大麻素CB1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和与肥胖有关的代谢紊乱。 本发明还提供了制备本发明的杂芳基 - 吡咯烷酮化合物或其药学上可接受的盐，含有它们的药物组合物的方法，以及用于预防或治疗肥胖症和与肥胖相关的代谢紊乱的方法。
-
5.发明授权Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same 有权作为SGLT2抑制剂的噻唑衍生物和包含其的药物组合物公开(公告)号：US08586550B2
公开(公告)日：2013-11-19
申请号：US13704081
申请日：2011-06-10
申请人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
发明人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
IPC分类号： A61K31/70 , A61K31/425 , C07H5/04 , C07H5/06 , C07D277/60
CPC分类号： C07H7/04 , C07D309/10 , C07D417/10 , C07D417/14 , C07D493/10 , C07H17/02
摘要： The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
摘要翻译： 本发明涉及一种具有对存在于肠和肾中的钠依赖性葡萄糖协同转运蛋白2（SGLT2）具有抑制活性的噻唑环的新型化合物，以及包含其作为活性成分的药物组合物，其可用于预防 或治疗代谢紊乱，特别是糖尿病。
-
6.发明申请Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same 有权噻唑衍生物作为SGLT2抑制剂和药物组合物组成公开(公告)号：US20130090298A1
公开(公告)日：2013-04-11
申请号：US13704081
申请日：2011-06-10
申请人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
发明人： Jinhwa Lee , Jeongmin Kim , Suk Ho Lee , Junwon Lee , Kwang-Seop Song , Eun-Jung Park , Min Ju Kim , Hee Jeong Seo , Sung-Han Lee , Eun Jung Son , Jong Yup Kim , Suk Youn Kang , Younggyu Kong
CPC分类号： C07H7/04 , C07D309/10 , C07D417/10 , C07D417/14 , C07D493/10 , C07H17/02
摘要： The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
摘要翻译： 本发明涉及一种具有对存在于肠和肾中的钠依赖性葡萄糖协同转运蛋白2（SGLT2）具有抑制活性的噻唑环的新型化合物，以及包含其作为活性成分的药物组合物，其可用于预防 或治疗代谢紊乱，特别是糖尿病。
-
7.发明授权C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same 有权C-芳基葡糖苷SGLT2抑制剂和包含其的药物组合物公开(公告)号：US08541380B2
公开(公告)日：2013-09-24
申请号：US13379301
申请日：2010-06-18
申请人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
发明人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
CPC分类号： C07D417/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10
摘要： A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
摘要翻译： 在肠和肾中存在对钠依赖性葡萄糖共转运体2（SGLT2）具有抑制活性的新型C-芳基葡糖苷化合物或其药学上可接受的盐或前药; 并且提供了包含其作为活性成分的药物组合物，其可用于预防或治疗代谢紊乱，特别是糖尿病。
-
8.发明申请SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS 失效作为CANNABINOID CB1受体拮抗剂的含硫吡唑杂交衍生物公开(公告)号：US20110178140A1
公开(公告)日：2011-07-21
申请号：US13120026
申请日：2008-09-25
申请人： Jinhwa Lee , Hee Jeong Seo , Min-Ah Kim , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Mi-Soon Kim
发明人： Jinhwa Lee , Hee Jeong Seo , Min-Ah Kim , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Mi-Soon Kim
IPC分类号： A61K31/433 , C07D417/04 , C07D413/04 , A61K31/4245 , A61P3/04
CPC分类号： C07D417/04 , C07D413/04
摘要： A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的新型含硫杂芳基 - 吡唑化合物或其药学上可接受的盐作为大麻素CB1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和与肥胖有关的代谢紊乱。 预防还提供其制备方法，含有该组合物的药物组合物，以及预防或治疗肥胖症和与肥胖有关的代谢紊乱的方法。
-
9.发明授权Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists 失效含硫吡唑杂环衍生物作为大麻素CB1受体拮抗剂公开(公告)号：US08309584B2
公开(公告)日：2012-11-13
申请号：US13120026
申请日：2008-09-25
申请人： Jinhwa Lee , Hee Jeong Seo , Min-Ah Kim , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Mi-Soon Kim
发明人： Jinhwa Lee , Hee Jeong Seo , Min-Ah Kim , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Mi-Soon Kim
IPC分类号： A61K31/433 , A61K31/4245 , A61P3/04 , C07D413/04 , C07D417/04
CPC分类号： C07D417/04 , C07D413/04
摘要： A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.
摘要翻译： 式（I）的新型含硫杂芳基 - 吡唑化合物或其药学上可接受的盐作为大麻素CB1受体反向激动剂或拮抗剂是有效的，其可用于预防或治疗肥胖症和与肥胖有关的代谢紊乱。 预防还提供其制备方法，含有该组合物的药物组合物，以及预防或治疗肥胖症和与肥胖有关的代谢紊乱的方法。
-
10.发明申请NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME 有权新型C-ARYL GLUCOSIDE SGLT2抑制剂和包含其的药物组合物公开(公告)号：US20120101051A1
公开(公告)日：2012-04-26
申请号：US13379301
申请日：2010-06-18
申请人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
发明人： Jinhwa Lee , Suk Ho Lee , Hee Jeong Seo , Min Ju Kim , Suk Youn Kang , Jeongmin Kim , Sung-Han Lee , Myung Eun Jung , Eun Jung Son , Kwang-Seop Song , Mi-Soon Kim
IPC分类号： A61K31/706 , A61P3/10 , A61P3/00 , C08B37/00 , A61K31/7056
CPC分类号： C07D417/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10
摘要： A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
摘要翻译： 在肠和肾中存在对钠依赖性葡萄糖共转运体2（SGLT2）具有抑制活性的新型C-芳基葡糖苷化合物或其药学上可接受的盐或前药; 并且提供了包含其作为活性成分的药物组合物，其可用于预防或治疗代谢紊乱，特别是糖尿病。
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.049 秒)
